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Abstract
Visceral leishmaniasis (VL) is one of the most important parasitic diseases with approximately 350 million people at risk. Due
to the non availability of an ideal drug, development of a safe, effective, and affordable vaccine could be a solution for
control and prevention of this disease. In this study, a potential Th1 stimulatory protein- Triose phosphate isomerase (TPI), a
glycolytic enzyme, identified through proteomics from a fraction of Leishmania donovani soluble antigen ranging from
89.9–97.1 kDa, was assessed for its potential as a suitable vaccine candidate. The protein- L. donovani TPI (LdTPI) was cloned,
expressed and purified which exhibited the homology of 99% with L. infantum TPI. The rLdTPI was further evaluated for its
immunogenicity by lymphoproliferative response (LTT), nitric oxide (NO) production and estimation of cytokines in cured
Leishmania patients/hamster. It elicited strong LTT response in cured patients as well as NO production in cured hamsters
and stimulated remarkable Th1-type cellular responses including IFN-a˜ and IL-12 with extremely lower level of IL-10 in
Leishmania-infected cured/exposed patients PBMCs in vitro. Vaccination with LdTPI-DNA construct protected naive golden
hamsters from virulent L. donovani challenge unambiguously (,90%). The vaccinated hamsters demonstrated a surge in
IFN-a˜, TNF-a´ and IL-12 levels but extreme down-regulation of IL-10 and IL-4 along with profound delayed type
hypersensitivity and increased levels of Leishmania-specific IgG2 antibody. Thus, the results are suggestive of the protein
having the potential of a strong candidate vaccine.
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Introduction
Visceral Leishmaniasis (VL) is a major public health problem
among the poor population with significant morbidity and
mortality worldwide wherein approximately 500,000 cases of VL
are reported each year, 90% occur in Bangladesh, Brazil, India,
Ethiopia, Kenya and Sudan, countries that are strongly related to
poverty [1,2,3]. In India, high incidence has been reported from
the states of Bihar, Assam, West Bengal and eastern Uttar Pradesh
where resistance and relapse are on the increase [4]. With the
advent of the HIV epidemics, the disease has emerged as an
important opportunistic infection in AIDS patients [5,6]. Available
chemotherapy for VL is far from satisfactory because antileishma-
nial drugs are costly with unpleasant side effects. The situation has
further worsened with emergence of drug resistance in various
regions of endemicity [5]. Therefore, attention has now been
shifted towards the development of effective vaccines. Although
induction of lifelong protection against re-infection in recovered
people demonstrates that a protective vaccine can be achieved, an
effective vaccine against human leishmaniasis has yet to be
discovered [7,8,9].
The characteristic clinico-pathological and immunological
features of active VL is fever, hepatosplenomegaly, cachexia,
pancytopenia, hypergammaglobulinemia and the absence of
parasite-specific cell-mediated immune responses (CMI) [10,11].
The major arms of CMI-Helper and cytotoxic T cells are known
to play an integral role in the immune response to Leishmania
infection, connecting the innate immune response to the
development of efficient adaptive cellular immunity, mainly
through IL-2 and IFN-c production. These two cytokines drive
the effector functions of macrophages and trigger a Th1 immune
response [12]. Hence, any intervention that helps the shift of the
immune response from Th2 type towards Th1 type will have a
major role in cure and prevention of VL and therefore, modalities
to immunopotentiate the Th1 arm of the immune response could
be exploited as vaccine candidates. There are reports that
protective immunity is achieved by upregulation of Th1 response
after a successful chemotherapy [13,14].
Based on this, recently, several potential protective antigens
from L. donovani were identified through proteomics that induced a
Th1 response in the PBMCs of cured/endemic Leishmania patients
[15,16]. Triose phosphate isomerase (TPI/TIM) is one of the vital
glycolytic enzyme which has been identified as T- cell stimulatory
protein. The protein is responsible for the reversible isomerisation
between glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone
phosphate (DHAP). Due to its key role in energy metabolism, as
well as its well-understood enzymatic and structural features, TPI
of a pathogenetic organism is often considered as a potential drug
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and vaccine targets [17,18]. The protein has been identified as a
protective antigen in flat worm-Schistosoma japonicum (SjTPI) [19]
and it has been demonstrated that a SjTPI DNA vaccine produced
a 27.9–30.2% worm reduction in mice [20,21].
In the present study we have cloned, expressed and purified
L.donovani TPI (LdTPI) and assessed the ability of recombinant
LdPTI (rLdTPI) to stimulate cellular response in the PBMCs of
cured patients of VL and in mononuclear cells of cured Leishmania
infected hamsters as well. The protein as a LdTPI-DNA was
further evaluated for its prophylactic efficacy in golden hamsters
(Mesocricetus auratus) which is a perfect experimental model for VL
as it simulate the clinical profile of the disease in humans [22,23].
Materials and Methods
Animal
Laboratory-bred male golden hamsters (Mesocricetus auratus, 45–
50 g) from the Institute’s animal house facility were used as
experimental host. They were housed in climatically controlled
room and fed with standard rodent food pellet (Lipton India Ltd.,
Bombay) and water ad libitum. The usage of hamsters was
approved by the Institute’s Animal Ethical Committee (protocol
number 150/09/Para/IAEC dated 23.10.2009).
Parasites
The L. donovani clinical strain 2001 was procured from a patient
admitted to the Kala-azar Medical Research Centre of the
Institute of Medical Sciences, BHU, Varanasi and was cultured in
vitro as described elsewhere [24]. Promastigotes were grown in
RPMI –1640 medium at 26uC (Sigma, USA) in 75 cm2 culture
flasks (Nunc) [25,26]. The strain has also been maintained in
hamsters through serial passage, i.e. from amastigote to amastigote
[25].
Preparation of Soluble L. donovani Promastigote Antigen
Soluble L. donovani promastigote antigen (SLD) was prepared as
per method described by Gupta et al. [15]. Briefly, log phase
promastigotes (109) were harvested from 3 to 4 days of culture and
washed four times in cold phosphate-buffered saline (PBS) and
resuspended in PBS containing protease inhibitors cocktail (Sigma,
USA) and subjected to ultrasonication and centrifugation at
40,0006g for 30 min. The protein content of the supernatant was
estimated by Lowry method [27] and stored at 270uC.
Cloning, Expression and Purification of L. donovani Triose
Phoaphate Isomeras (LdTPI)
RNA was isolated from 108 promastigotes of L. donovani, by
Trizol (Sigma) and cDNA was synthesized by Moloney murine
leukemia virus reverse transcriptase as per the manufacturer’s
protocol (Fermentas). Resulting cDNA was treated with DNase
(10 mg/ml; Fermentas). LdTPI gene was amplified using Taq
Polymerase (Takara) lacking a 3¢–5¢ exonuclease activity. PCR
was performed using LdTPI-specific primers (based on the L.
infantum - TPI gene sequence): forward, 5- GGATC-
CATGTCCGCCAAGCCCCAGCCGATC-3 and reverse, 5-
GAATTCTCACTTCCGGGTGGCATCAATGATGTC-3
(BamHI and EcoRI site underlined) in a Thermocycler (Bio-Rad)
under conditions at one cycle of 95uC for 2 min, 30 cycles of 95uC
for 1 min, 54uC for 30 sec, and 72uC for 1 min, and finally one
cycle of 72uC for 10 min. Amplified PCR product was electro-
phoresed in agarose gel and eluted from the gel by Gen Elute
Columns (Qiagen). Eluted product was ligated in pTZ57R/T (T/
A) cloning vector (Fermentas) and transformed into competent
Escherichia coli (E. coli) DH5a´ cells. The transformants were
screened for the presence of recombinant plasmids with the
LdTPI insert by restriction digestion. Isolated positive clones were
sequenced from DNA sequencing facility, Department of Bio-
chemistry, South Campus- Delhi University (New Delhi), India
and submitted to the NCBI http://www.ncbi.nlm.nih.gov/
nuccore/EU867389.1 (accession no. EU920069.1). LdTPI was
further sub-cloned at the BamHI and EcoRI site in bacterial
pET28a vector (Novagen). The expression of LdTPI was checked
in bacterial cells by transforming the LdTPI + pET28a construct in
E. coli rosetta strain. The transformed cells were inoculated into 5-
ml test tube Luria- Bertani medium (LB) and allowed to grow at
37uC in a shaker at 220 rpm. Cultures in logarithmic phase (at
OD600 of ,0.5–0.6) were induced for 15–18 h with 1.0 mM
isopropyl-b-D-thiogalactopyranoside (IPTG) at 18uC. After in-
duction, 1 ml cells were lysed in 100 ml sample buffer (50 mM
Tris-HCl (pH 8), 10% glycerol, 10% SDS, and 0.05% bromo-
phenol blue, with 100 mM DTT) and whole cell lysates (WCL)
were analyzed by 12% SDS-PAGE. Uninduced control culture
was analyzed in parallel. The over expression of rLdTPI was
visualized by staining with coomassie – R250 stain (sigma).
Purification was carried out by taking 200 ml of LB medium
containing 34 mg/mL of chloramphenicol and 35 mg/mL kana-
mycin, inoculated with E. coli rosetta strain transformed with
pET28a + LdTPI, and grown at 37uC to an O.D.600 of ,0.6.
Recombinant protein expression was induced by addition of
1 mM (IPTG,Sigma) and the culture was incubated at 18uC for an
additional 15–18 h. The rLdTPI was purified by affinity
chromatography using Ni2+-NTA chelating resin to bind the
His6-tag fusion peptide derived from the pET28a vector. The cell
pellet was resuspended in 4 ml of lysis buffer (50 mM Tris-HCL
pH 8.0, 300 mM NaCl, and 20 mM imidazole,) containing 1:200
dilution of protease cocktail inhibitor (Sigma) and 1% Triton X-
100, incubated for 30 min on ice with 1 mg/ml lysozyme (Sigma),
and the suspension was sonicated for 10620 sec (with 30 s
intervals between each pulse) on ice. The sonicated cells were
centrifuged at 15,000 g for 30 min, and the supernatant was
incubated at 4uC for 1 h with the 2 ml of Ni2+-NTA Superflow
resin (Qiagen, Hilden, Germany) previously equilibrated with lysis
buffer. After washing with buffer (50 mM Tris-HCL (pH 8.0),
300 mM NaCl and 1% Triton X- 100 or Triton X- 114 ),
containing different concentrations of imidazole i.e. 20, 50 and
100 mM, the purified recombinant rLdTPI was eluted with
elution buffer (50 mM Tris-HCL pH 7.5, 100 mM NaCl, and
250 mM imidazole). The eluted fractions were analyzed by 12%
SDS–PAGE and the gels were stained with Coomassie brilliant
blue R-250 (Sigma–Aldrich, St. Louis, USA). For in vitro
experiments, imidazole from eluted protein was easily removed
by dialysis using a 10 kDa molecular cut off dialysis device. The
presence of endotoxin was tested by QCL-1000H Chromogenic
LAL kit (Lonza). The protein content of the fractions was
estimated by the Bradford method using bovine serum albumin
(BSA) as standard.
Production of Polyclonal Antibodies Against the rLdTPI
and Western Blot Analysis
The purified rLdTPI protein was used for raising antibodies in
New Zealand white rabbit. Rabbit was first immunized using
50 mg of rLdTPI in Freund’s complete adjuvant. After 15 days, the
rabbit was given 3 booster doses of 25 mg rLdTPI each in
incomplete Freund’s adjuvant at 2-weeks interval and blood was
collected for serum 8 days after the last immunization. For
immunoblotting experiment, purified rLdTPI protein and SLD
were resolved on 12% SDS–PAGE and transferred on to
nitrocellulose membrane using a semi-dry blot apparatus (Amer-
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sham) [28]. After overnight blocking in 5% BSA, the membrane
was incubated with antiserum to the rLdTPI protein at a dilution
of 1:4000 for 120 min at room temperature (RT). The membrane
was washed three times with PBS containing 0.5% Tween - 20
(PBS-T) and then incubated with goat anti-rabbit IgG HRP
conjugate (Bangalore Genie) at a dilution of 1:10,000 for1 h at
room temperature. Blot was developed by using diaminobenzidine
+ imidazole +H2O2 (Sigma).
Expression of LdTPI-DNA Construct in Mammalian Cell
Line
The expression of LdTPI–DNA vaccine was further checked in
mammalian cells by transfecting the LdTPI–DNA vaccine
construct in HEK- 293T cells. For transfection and vaccination
studies, endotoxin- free plasmid DNA was isolated using an
Endofree plasmid purification Maxi kit as per the manufacturer’s
protocol (Qiagen). For confirmation of the proteins expressed by
the LdTPI–DNA vaccine construct, 2 x105 HEK - 293T cells were
grown in four-chamber slides and transfected with the blank
pcDNA3 plasmid and LdTPI–DNA vaccine construct in serum-
free DMEM (Life Technologies) using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. Expression
was confirmed by western blotting. For western blotting, the lysate
of stably transfected HEK- 293T cells was prepared and subjected
to SDS-PAGE. Thereafter, the protein bands were electrophoret-
ically transferred to nitrocellulose membrane. To detect the
expressed protein, a primary polyclonal antibody against rLdTPI
was used at 1:5000 dilution followed by 1:10000 dilution of HRP-
conjugated goat anti-rabbit IgG secondary antibody (Bangalore
Genei, Bangalore, India) developed by using diaminobenzidine +
imidazole +H2O2 (Sigma).
Patients and Isolation of Peripheral Blood Mononuclear
Cells (PBMCs)
The study was based on a convenience human sample of 27
belonging to the following categories/groups:
N [1] Ten treated cured patients (6 males and 4 females, age
ranging from 5–40 years) from hyper-endemic areas of Bihar.
All the patients had received complete course of Amphotericin
B and had recovered from VL. Samples were collected from 2
months to 1 year after the completion of treatment. Diagnosis
was established in all cases by demonstration of parasites in
splenic aspirates and found negative at the time of study.
N [2] Seven endemic household contacts (3 females and 4 males,
age range-15 to 45 years) that neither showed clinical
symptoms nor received any treatment for Kala-azar.
N [3] Five infected patients (3 males and 2 females, age range- 5
to 45 years) showing clinical symptoms of Kala-azar.
N [4] Five normal healthy donors (3 males and 2 females, age
range 25–35 years) from non-endemic areas, without any
history of leishmaniasis, served as negative control.
The study was approved by the Ethics committee of the Kala-
azar Medical Research Centre, Muzaffarpur (Protocol # EC-
KAMRC/Vaccine/VL/2007–01). All the human subjects under-
went clinical examination by a local physician for leishmanial and
other possible infections. Informed consent was obtained from
each subject before clinical examination and sampling.
Heparinized venous blood (10 ml each) was collected from all
the study subjects and peripheral blood mononuclear cells
(PBMCs) were isolated from blood by Ficoll Hypaque density
gradient centrifugation (Histopaque 1077, Sigma, USA) as
described by Garg et al. [24]. A final suspension of 16106 cells/
ml was made in complete RPMI medium (cRPMI) after
determining cell viability by trypan blue staining method.
Treatment of L. donovani Infected Hamsters and Isolation
of Mononuclear Cells (Lymph Node Cells)
Approximately 20 hamsters, infected with 107 amastigotes
intracardially, were assessed one month later for parasitic burden
by splenic biopsy through a small incision in the upper left quarter
of the abdomen and a small piece of splenic tissue was cut and dab
smears were made on slides. The incised portion was stitched with
nylon suturing thread. Following biopsy, an adequate amount of
antibiotic powder (Neosporin) was applied on the stitched portion
and finally sealed with tincture of benzoin. In addition, neosporin
sulphate (100 mg/kg of body weight) was also given orally the day
before and the day after the biopsy for healing. The smears were
fixed in methanol and stained with Giemsa stain and the number
of amastigotes/1000 cell nuclei was counted. The animals
harbouring .25–30 amastigotes/100 macrophage cell nuclei
were then treated with antileishmanial drug-Miltefosine (Zentaris,
Germany) at 40 mg/kg bodyweight daily for 5 days. The animals
were reassessed for complete cure by splenic biopsy performed on
day 30 post-treatment. Mononuclear cells were separated from
lymph nodes of cured, infected as well as normal hamsters
following the protocol of Garg et al. [24] and a suspension of 106
cells/ml was made in cRPMI. These cells were employed for
lymphoproliferative assay and for the estimation of NO produc-
tion.
Assessment of Prophylactic Efficacy of LdTPI-DNA Vaccine
in Hamsters to Leishmania Challenge
Four experimental groups each having 12–15 hamsters were
taken for the study. The hamsters of Group I was immunized
intramuscularly (i.m.) with LdTPI-DNA (100 mg/100 ml PBS/
animal) alone whereas groups II to IV served as controls. The
animals of group II were vaccinated with 100 mg of pcDNA3
(blank vector)/100 ml of PBS and that of group III served as
unvaccinated but infected control. The animals of group IV did
not receive either DNA vaccine or Leishmania infection and served
as normal control. Two booster doses of 100 mg LdTPI-DNA were
given i.m. to group I on day 14 and 21. Day twenty-eight days
after the first vaccination dose, all the vaccinated and unvacci-
nated control groups were challenged intracardially with 100 ml of
108 cell/ml late log phase promastigotes (107) of L. donovani,
isolated on day 3–4 of culture which contains mostly late log phase
or stationary or metacyclic forms. The body weight and that of the
spleen and liver (on necropsy) of hamsters of all of the
experimental groups were assessed, on necropsy, at different time
intervals, i.e., on days 0, 45, 90 and 120 post-challenge (p.c.). The
assessment of parasite burden was done in spleen, liver and bone
marrow of vaccinated hamsters at different time intervals, i.e. on
days 0, 45, 90, 120 p.c. Peritoneal exudates cells, inguinal lymph
nodes and blood were also collected at these time points to obtain
cells and sera for evaluation of cellular and antibody responses as
per protocols described below. The criterion for prophylactic
efficacy was the assessment of parasite load as the number of
amastigotes/1000 cell nuclei in each organ in comparison to the
unvaccinated controls and the percentage inhibition (PI) was
assessed in comparison to the unvaccinated control by following
formula [29] PI = (No. of parasite count from infected control
2No. of parasite from vaccinated group/No. of parasite count
from infected control) 6 100. DTH was performed by injecting
50 mg/50 ml of SLD in PBS intradermally into one footpad and
Evaluation of LdTPI as a Potent Vaccine Candidate
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PBS alone into the other one of each of the vaccinated and
unvaccinated controls. The response was evaluated 48 h later by
measuring the difference in footpad swelling between the two with
and without SLD for each animal [30].
Immunological Assays
Assessment of Lymphocyte proliferative responses (LTT)
in cured/exposed patients and hamsters. PBMCs and
mononuclear cells (16106 cells/ml) of cured/exposed patients
and normal, infected (30 days p.c.) as well as cured hamsters
respectively, was cultured in 96-well flat bottom tissue culture
plates (Nunc, Denmark). This assay was carried out as per protocol
described by Kushawaha et al. [31]. About 100 ml of predeter-
mined concentration of mitogens phytohaemoglutinin (PHA,
10 mg/ml Sigma, USA) for Patient’s PBMCs, Concavalin A
(Con A, 10 mg/ml, Sigma, USA) for hamster’s mononuclear cells,
as well as rLdTPI and SLD (10 mg/ml each) were added to the
wells in triplicate. Wells without stimulants served as blank
controls. Cultures were incubated at 37uC in a CO2 incubator
with 5% CO2 for 3 days in the case of the mitogens, and for 5 days
in the case of the antigens. Eighteen hours prior to termination of
experiment, 50 ml of XTT (Roche diagnostics) was added to
100 ml of supernatants of each well and absorbance measured at
480 nm with 650 nm as reference wavelength.
Estimation of Nitric oxide (NO) activity in macrophages
of hamsters. Isolated mononuclear cells from all the three
study groups of hamsters viz. Normal, infected (30 post infected)
and cured, were suspended in culture medium and plated at 105
cells/well and stimulated for 3 days in case of mitogen (LPS,
10 mg/ml) and 5 days in case of antigens (rLdTPI, SLD) at 10 mg/
ml. The presence of nitric oxide (NO) was assessed using Griess
reagent (Sigma, U.S.A) in the culture supernatants of naive
hamster peritoneal macrophages [24] after the exposure with
100 ml supernatant of stimulated mononuclear cells. The super-
natants (100 ml) collected from macrophage cultures 24 h after
incubation at 37uC in CO2 incubator was mixed with an equal
volume of Griess reagent (Sigma, USA) and left for 10 min at
room temperature. The absorbance of the reaction was measured
at 540 nm in an ELISA reader [32]. The nitrite concentration in
the macrophages culture supernatant samples was extrapolated
from the standard curve plotted with sodium nitrite. The same
protocol for measuring NO production was used in LdTPI-DNA
vaccination study.
Assessment of Cytokine levels- IFN-a˜/IL-12/IL-10 in
PBMCs of cured/endemic patients. Culture of PBMCs
(16106 cells/ml) from human patients was set up in 96-well
culture plates and rLdTPI as well as SLD were added in triplicate
wells at a concentration of 10 mg/ml. The level of IFN-a˜, IL-12
and IL-10 was estimated by enzyme-linked immuno-sorbent assay
(ELISA) kit (OptEIA set, Pharmingen) after 5 days of incubation
with antigen using supernatants. The results were expressed as
pictograms (pg) of cytokine/ml, based on the standard curves of
the respective cytokine provided in the kit. The lower detection
limits for various cytokines were as follows: for IFN-a˜- 4.7 pg/ml,
for IL-12p40- 7.8 pg/ml and for IL-10 27.0 pg/ml.
Quantification of mRNA cytokines and inducible NO
synthase (iNOS) in hamsters by Real time-PCR (QRT-
PCR). QRT-PCR was performed to assess the expression of
mRNAs for various cytokines and iNOS in splenic cells. Splenic
tissues were taken from each of the three randomly chosen
animals. Total RNA was isolated using Tri-reagent (Sigma-
Aldrich) and quantified by using Gene-quant (Bio-Rad). One
microgram of total RNA was used for the synthesis of cDNA using
a first-strand cDNA synthesis kit (Fermentas). For qRT- PCR,
primers were designed using Beacon Designer software (Bio-Rad)
on the basis of cytokines and iNOS mRNA sequences available on
PubMed [22] (Table 1). qRT-PCR was conducted as per the
protocol described earlier by Kushawaha et al. [31]. Briefly, it was
carried out with 12.5 ml of SYBR green PCR master mix (Bio-
Rad), 1 mg of cDNA, and primers at a final concentration of
300 nM in a final volume of 25 ml. PCR was conducted under the
following conditions: initial denaturation at 95uC for 2 min
followed by 40 cycles, each consisting of denaturation at 95uC
for 30 s, annealing at 55uC for 40 s, and extension at 72uC for
40 s per cycle using the iQ5 multicolor real-time PCR system (Bio-
Rad). cDNAs from infected hamsters were used as ‘‘comparator
samples’’ for quantification of those corresponding to test samples
whereas in vaccination studies. All quantifications were normal-
ized to the housekeeping gene HPRT. A no-template control
cDNA was included to eliminate contaminations or nonspecific
reactions. The cycle threshold (CT) value was defined as the
number of PCR cycles required for the fluorescence signal to
exceed the detection threshold value (background noise). Differ-
ences in gene expression were calculated by the comparative CT
method [33]. This method compares test samples to a comparator
sample and uses results obtained with a uniformly expressed
control gene (HPRT) to correct for differences in the amounts of
RNA present in the two samples being compared to generate a
DCT value. Results are expressed as the degrees of difference
between DCT values of test and comparator samples.
Measurement of antibody response in hamsters. The
level of IgG antibody and its isotypes in sera samples of hamsters of
different experimental groups was measured as per protocol
described by Kushawaha et al. [31]. Briefly, 96-well ELISA plates
(Nunc) were coated with SLD (0.2 mg/100 ml/well) overnight at
4uC and blocked with 1.5% BSA at room temperature for 1 h.
Sera was used at a dilution of 1/100 for IgG, IgG1, and IgG2 and
kept for 2 h at room temperature. Biotin-conjugated mouse anti-
Armenian and Syrian hamster IgG, IgG1 and biotinylated anti-
Syrian hamster IgG2 (BD Pharmingen) were added for 1 h at
room temperature at 1/1000 dilutions and were further incubated
Table 1. Sequences of forward and reverse primers of
hamster cytokines used for quantitative real time -PCR.
S.N. Primer Primer Sequence
1 HPRT Forward 59 GATAGATCCACTCCCATAACTG 39
Reverse 5¢ TACCTTCAACAATCAAGACATTC 39
2 TNF-a´ Forward 5¢ TTCTCCTTCCTGCTTGTG 3¢
Reverse 59 CTGAGTGTGAGTGTCTGG 39
3 IFN-a˜ Forward 59 GCTTAGATGTCGTGAATGG 39
Reverse 5¢ GCTGCTGTTGAAGAAGTTAG 39
4 IL-12 Forward 59 TATGTTGTAGAGGTGGACTG 39
Reverse 59 TTGTGGCAGGTGTATTGG 39
5 TGF-aˆ Forward 59 ACGGAGAAGAACTGCTGTG 39
Reverse 59 GGTTGTGTTGGTTGTAGAGG 39
6 IL-4 Forward 59 GCCATCCTGCTCTGCCTTC 39
Reverse 59 TCCGTGGAGTTCTTCCTTGC 39
7 IL-10 Forward 59 TGCCAAACCTTATCAGAAATG3’
Reverse 59 AGTTATCCTTCACCTGTTCC 39
8 iNOS Forward 59 CGACGGCACCATCAGAGG 3¢
Reverse 59AGGATCAGAGGCAGCACATC 39
doi:10.1371/journal.pone.0045766.t001
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with streptavidin-conjugated peroxidase at 1/1000 (BD Pharmin-
gen) for 1 h. Finally, the substrate O-phenylenediamine dihydro-
chloride (Sigma-Aldrich) was added and the plate was read at
492 nm.
Post-challenge Survival
Survival of hamsters belonging to group I was checked until day
180 p.c. in comparison to the normal hamsters. Animals in all of
the groups were given proper care and were observed for their
physical conditions until their survival period. Survivals of
individual hamsters were recorded and mean survival period was
calculated.
Statistical Analysis
Results were expressed as mean6S.D. In each experiment 12–
15 animals were used in each group. Two sets of experiments were
performed and the results were analyzed by one-way ANOVA test
followed by Dunnets or Tukeys post which ever appropriate at
each case using Prism Graphpad software program. The upper
level of significance was chosen as p,0.001 (highly significant).
Results
LdTPI was Cloned, Sequenced, Expressed in E. coli Rosetta
Strain and HEK Cell Line
The LdTPI gene of L. donovani was successfully cloned and
sequenced which was 99% homologous with L. infantum TPI
(Table 2). Further it was expressed and purified by affinity
chromatography using Ni2+ NTA coloums. The expression
revealed that the size of the expressed proteins was , 28 kDa
(Fig1 A). The rLdTPI protein was purified and eluted at 250 mM
imidazole concentration (Fig1 B). Immunoblots of lysates from L.
donovani promastigotes was performed with the polyclonal anti-
rLdTPI antibody which detected one dominant protein species of
,27 kDa (Fig1 C). Western blot analysis of rLdTPI with patients’
sera also showed a dominant protein band of ,28 kDa. The
expression of rLdTPI in HEK cell line was confirmed by western
blotting using anti-rLdTPI antibody (Fig1D). The results showed
that the recombinants were correctly constructed and expressed in
mammalian cell line.
rLdTPI Stimulation Induced Strong Lymphoproliferative
and NO Responses in Cured Hamsters
The cellular responses of lymph node cells of cured hamsters
were assessed by XTT against the mitogen, i.e. Con A as well as
SLD and rLdTPI. The responses were compared with that of
normal as well as L. donovani infected groups that served as
controls. Concavalin A controls showed a good lymphoprolifer-
ative (LTT) response in normal, active VL and cured groups,
indicating the procedural sensitivity. The results of the prolifer-
ative response of mononuclear cells against rLdTPI showed
considerably higher stimulation in cured hamsters (mean OD-
2.25960.038) than infected hamsters (1.57860.193). The differ-
ence was statistically significant (P,0.001) (Fig. 2 A).
NO is the critical killing effector molecule against leishmaniasis
produced by IFN-a˜ stimulated and inducible NO synthase induced
classical macrophages, hence its production in peritoneal macro-
phages of cured hamsters, was studied after 24 h of incubation in
the presence of rLdTPI and SLD. For comparison, NO
production in mitogenic (LPS) stimulated and unstimulated cells
served as positive and negative controls respectively. NO
production was recorded to be higher against rLdTPI (p,.001)
(Fig. 2 B).
rLdTPI Stimulates PBMCs from Leishmania Infected
Cured/endemic to Proliferate and to Express a Robust Thl
Cytokine Profile
We further validated the cellular responses (LTT and cytokine
levels) of rLdTPI in PBMCs of cured patients, endemic and L.
donovani-infected donors. Individual donors in each study group
were found to elicit different responses. Proliferation and cytokine
responses of PBMCs from patients with active VL/cured/endemic
were compared using rLdTPI and SLD. Endemic control, cured
and infected patients exhibited good proliferation against PHA,
indicating the procedural sensivity. PBMCs from all the cured and
active VL patients proliferated in response to rLdTPI with mean
OD values of 2.01960.103 and 1.37860.123 higher values than
SLD (mean OD values of 1.15860.335) and 0.367360.118)
respectively (p,.001) (Fig. 3 A).
To assess the Th1/Th2 stimulatory potential of the LdTPI we
further studied the cytokine levels viz. IFN-a˜ and IL-12 in PBMCs
from cured/infected patients as well as in endemic contacts against
rLdTPI. The levels of IL-12 and IFN-c were observed to be higher
in the supernatants of cured patients with a range of 565.34–
1945.75 pg/ml and 338.28–1458.68 pg/ml respectively as com-
pared to endemic contacts (459.07–1280.87 pg/ml and 243.63–
1385.13 pg/ml respectively). On the contrary, very low level of IL-
10 cytokines against rLdTPI was detected in supernatants of cured
(10.69–44.52 pg/ml) patients followed by endemic contacts
(ranging from 9.3–40.23 pg/ml). PBMCs of cured/endemic
contacts generated a mixed Th1/Th2 cytokine profile against
SLD wherein high levels of IL-10 very little level of IFN-c, and IL-
12p40 were noticed in response to SLD in cured/endemic
contacts(Fig. 3 B-D). We have not able to detect lymphoprolifer-
ative response and these cytokines in non endemic and infected
control against rLdTPI.
Vaccination with LdTPI-DNA Vaccine Induced
Outstanding Protection in Hamsters against L. donovani-
challenges
The ability of rLdTPI to stimulate T cell response and Th1
profile suggested that vaccintion with LdTPI may provide
protection in L. donovani-infected hamsters. The LdTPI-DNA
vaccinated hamsters were found to be optimally protected
(,90%) from the challenge infection of L. donovani. An increase
from 103 to 104 parasites in all of the groups, except in the LdTPI-
DNA vaccinated group, was seen in Giemsa-stained splenic smears
from days 45 to 120 p.c. In the vaccinated group, parasite loads
decreased from 26102 on day 45 to a very low level (p,0.001) by
day 120 p.c. Similarly, in liver and bone marrow, parasite loads
decreased sharply after day 45 p.c. and parasites were almost
absent by day 180 p.c. in the vaccinated group (Fig.4 A-C).
Cultivation of the spleen, liver, and lymph node tissues from the
vaccinated hamsters in vitro yielded no promastigotes after
prolonged incubation for 3 week. The LdTPI-DNA vaccinated
hamsters survived the challenges of L. donovani and remained
healthy more than 8 months. In contrast, hamsters vaccinated with
the pcDNA3 vector and infected control survived for only 3–4
months.
LdTPI-DNA Vaccination Stimulates DTH, Mitogenic and
Leishmania-specific Cellular Responses
DTH, an index of cell mediated immunity in vivo, and an Ag
specific in vitro T cell proliferation assay revealed the status of
cellular responses generated in vaccinated animals. We were
therefore interested to see the DTH and proliferative responses
elicited by vaccinated and challenged animals. Challenge with L.
Evaluation of LdTPI as a Potent Vaccine Candidate
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45766
donovani induced enhanced DTH responses and LdTPI-specific T
cell proliferation in all vaccinated hamsters at different time
periods as compared to blank vector and infected controls. LdTPI-
DNA vaccinated hamsters displayed significant DTH responses,
which increased progressively and was higher than those of the
control groups (p,0.01) at all time points for the duration of the
experiments for up to 120 days (Fig.5 A). In vitro stimulation of the
mononuclear cells with Con A showed comparable proliferative
responses at high levels in all of the groups when assayed before
challenges (day 0). ConA induced LTT response remained
elevated in LdTPI-DNA vaccinated animals as much as those of
the normal hamsters throughout the entire post challenged period,
but it decreased precipitously with time in all of the other control
groups. In SLD-specific re-stimulation assays, the lymphoprolifer-
ative response was negative for all the groups on pre-vaccination
and for the non vaccinated control groups throughout the p.c.
Figure 1. Cloning, expression and purification LdTPI. Expression of LdTPI in prokaryotic cells, whole cell lysate (WCL) of pET 28a+LdTPI
transformed E. coli separated on 12% SDS-PAGE and stained with Coomassie brilliant blue, M: Molecular wt. markers; Lane 1: WCL before IPTG
induction, lane 2: WCL after IPTG (1.0 mM) induction at 18uC (A); Purification of rLdTPI, M: Molecular wt. markers, Lane 1: wash fraction containing
nonspecific proteins also and Lane 3 & 4: eluted purified protein (B); Western blot analysis using anti-LdTPI antibody raised in rabbit, M: Molecular wt.
Markers, Lane 1: uninduced WCL of E. coli, Lane 2: induced WCL of E. coli, Lane 3&4: WCL and SLD of L. donovani, and Lane 5: purified rLdTPI (C);
Western blot analysis of rLdTPI with patients’ serum. M: Molecular wt markers, Lane 1&2 blot with rLdTPI (D). Confirmation of LdTPI expression in HEK
cell line by western blotting. M: Molecular wt. markers, Lane 1: WCL of non transfected cells, Lane 2: WCL of LdTPI-DNA construct transfected cells (E).
doi:10.1371/journal.pone.0045766.g001
Table 2. Homology of LdTPI of L. donovani with other
Leishmania species.
Species Homology (%)
Leishmania infantum 99
Leishmania major 94
Leishmania braziliensis 84
doi:10.1371/journal.pone.0045766.t002
Figure 2. Cellular responses of rLdTPI in hamsters. LTT response
of mononuclear cells (lymph nodes) from normal, L. donovani infected
(30 day p.c.) and treated hamsters in response to Con A, SLD and rLdTPI
at 10 mg/ml each. Proliferation was represented as mean O.D of
stimulated culture - mean O.D of unstimulated control. Each bar
represents the pooled data (mean 6 S.D. value) of 6 hamsters and the
data represent the means of triplicate wells 6 S.D. of each hamster (A);
Nitric oxide production (mM) by peritoneal macrophages of hamsters (n
= 5). The peritoneal macrophages were primed with 100 ml superna-
tants of stimulated mononuclear cells (3 days with mitogen and 5 days
with antigens) of normal, infected and cured hamsters in response to
rLdTPI, SLD and LPS respectively at 10 mg/ml each (B); The estimation of
NO production was done using Greiss reagent in supernatants collected
from macrophage cultures 24 h after incubation and the absorbance of
the reaction product was measured at 540 nm. Significance values
indicate the difference between the SLD and rLdTPI stimulation (*,
p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0045766.g002
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period (normal, infected and vector). Cells from LdTPI-DNA
vaccinated hamsters produced a significantly higher response
(p,0.001), which reached almost to the maximum on day 90
(Fig.5 B&C).
Lymphocyte-mediated activation of macrophages to produce
NO for leishmanicidal activities was found to differ between
control and experimental groups of hamsters. Supernatants from
stimulated mononuclear cells of hamsters vaccinated with the
LdTPI-DNA, when incubated with naive macrophages produced
significant (p,0.001) amounts of nitrite (24 mg)which was ,5
fold more than that of unimmunized infected controls and ,8-
fold more than the normal control group on day 90 p.c. (Fig.5
D&E).
LdTPI-DNA Vaccination Favours the Development of Th1-
type Cytokine Profile as Determined by Quantitative
Real-time PCR
It is well established that the cytokine milieu at the initiation of
infection is critical in determining disease outcome [34,35]. Since
LdTPI elicited Th1 response in patients’ PBMCs, we further
examined the cellular immune responses in LdTPI -DNA
vaccinated hamsters. The expression of Th1 and Th2 mRNA
cytokines was evaluated by real-time PCR on days 45 and 90 p.c.
The expression of iNOS transcripts was observed to be
significantly (p,0.001,) elevated by , 4 fold in LdTPI -DNA
vaccinated hamsters on day 90 p.c. (Fig.6 A). Similarly, at the
same time point, the expression of TNF-a´ was also significantly
Figure 3. Cellular responses of LdTPI in human samples. LTT response, proliferation was represented as mean O.D of stimulated culture -
mean O.D of unstimulated control. Each bar represents the pooled data (mean 6 S.D. value) of stimulated PBMCs of each group (A); Th1 and Th2
cytokine production in PBMCs from individuals of cured VL patients (n = 7) and endemic controls (n = 5) in response to rLdTPI and SLD antigens, each
data point represents one individual (B-D). Values are given as concentration in pg/ml. The statistical significances are given between infected vs
cured and infected vs endemic individuals. (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0045766.g003
Figure 4. Parasite burden (no. of amastigotes per 1000 cell nuclei). Parasite load in the spleen (A), liver (B), and bone marrow (C) of infected
control, vector (pcDNA) control as well as LdTPI-DNA vaccinated hamsters on days 0, 45, 90, 120, and 180 p.c. Significance values indicate the
difference between the vaccinated groups and infected group (p,0.05; p,0.01; and p,0.001).
doi:10.1371/journal.pone.0045766.g004
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higher (p,0.001) by , 3 fold in the vaccinated group in
comparison to L. donovani-infected group (Fig.6 B). The expression
of IL-12 which was least expressed in the infected group on day
90 p.c. but was significantly (p,0.001) expressed by ,5 fold
higher in vaccinated hamsters on days 90 p.c (Fig.6 C). IFN-c was
suppressed in the infected group on day 45and 90.p.c, but was
significantly higher by , 3 fold in the vaccinated group on day90
(p,0.001) p.c. (Fig.6 D). The level of IL-10, IL-4 and TGF-aˆ were
significantly (p,0.001) up-regulated in infected and vector control,
indicating progressive VL at different time intervals while these
cytokines were highly down regulated in vaccinated hamsters
reflecting the situation in cured VL (Fig.6 E–G).
Figure 5. Cellular response against SLD in normal, infected control, vector (pcDNA) control as well as LdTPI-DNA vaccinated
hamsters at different time intervals post challenge. (A) DTH response (mm); (B&C) LTT response (mean O.D value) to SLD and ConA in normal,
infected control, vector (pcDNA) control as well as LdTPI-DNA vaccinated hamsters on days 45 and 90 post challenge; (D&E) NO production (mM) to
LPS and SLD in the naive macrophages co-incubated with supernatants of mononuclear cells isolated from LdTPI-DNA-vaccinated hamsters in
comparison to the unimmunized infected controls, vector-immunized controls, and uninfected normal hamsters on day 45 and day 90 post
challenge. The LdTPI-DNA vaccinated hamsters survived the challenges of L. donovani and remained healthy more than 8 months. In contrast,
hamsters vaccinated with the pcDNA3 vector and infected control survived for day 90 p.c. Significance values indicate the difference between the
vaccinated groups and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0045766.g005
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LdTPI-DNA Vaccination alters Leishmania-specific IgG and
its Isotypes
Since the outcome of VL may be determined by the extent of
immune system activation, it was highly important to characterize
the changes in the immunoglobulin level after immunization. It is
well established that the cytokines such as IFN-a˜ and IL-4 direct
immunoglobulin class switching of IgG2a and IgG1, respectively.
The anti-Leishmania IgG and IgG1, a surrogate marker of Th2
cell differentiation were elevated progressively with time to a high
Figure 6. Splenic iNOS and cytokine mRNA expression profile analysis of normal and LdTPI-DNA vaccinated hamsters on days 45
and 90 p.c. by quantitative real-time PCR. Significance values indicate the difference between the vaccinated group and infected group (*,
p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0045766.g006
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level in all groups, except the LdTPI-DNA vaccinated, in which
case they remained essentially in the background levels of the
nonimmunized and unchallenged normal and vector immunized.
In contrast, LdTPI-DNA vaccinated animals were the only group
that showed a significant elevation by 2- to 3 fold over the others
(p,0.01) in the level of IgG2, a surrogste marker for Th1 type
immune response (Fig. 7). As a measure of CMI, the elevation of
IgG2 was consistent with the development of effective immune
responses.
Discussion
It is established through clinical studies that human VL has a
complex immunology characterized by mixed T-helper-1(Th1)/T-
helper-2 (Th2) cell milieu, where a suppressed Th1 response along
with an elevated Th2 is the hallmark of the active disease. On the
other hand, protective immunity is achieved by upregulation of
Th1 response after a successful chemotherapy [13]. Recovery from
VL is always associated with immunity to subsequent infection and
induction of Th1 cytokines, dominated by IFN-c, which activate
macrophages to kill the intracellular organisms, primarily through
H2O2- dependent [36] and NO-mediated mechanism [37,38].
Therefore, the antigens that are involved in the induction and
recall of such memory Th1 cells are considered to be of great
interest in the vaccine design strategy against VL.
A large number of leishmanial antigens against experimental
leishmaniasis have been attempted for vaccination, mainly against
the cutaneous form. However, there is still only a little progress
with a limited number of potential candidates to combat VL
through vaccination [39,40]. During the last decades there are
reports of defined antigens protective against experimental VL
such as H2A/H2B, LelF-2, KMP11, HASPB, A2, ORFF, LACK
and CPB [31,41,42,43,44,45,46], which have been found to be
either partially protective or yet at the stage of experimental
evaluation [47,48,49]. So far successful immunization trials were
done with viz FML, FML-QuilA Saponin etc against canine
visceral leishmaniasis (14–19). However, as compared to defined
single antigen, polyprotein vaccines viz. LEISH-F1 (formerly-
Leish111f), consisting of three recombinant antigens: Leishmania
elongation initiation factor (LeIF), thiol-specific antioxidant (TSA)
and L. major stress-inducibleprotein-1(LmSTI1) in combination
with MPL-SE have been reported to afford better protection
against experimental VL. This vaccine is the only one that has
successfully cleared the clinical trial for safety and immunogenicity
against leishmaniasis [50,51] and is still under clinical efficacy trial.
Hence, there is a need for identifying new antigens from L. donovani
ideally relying on correlates of protective immunity.
On the basis of the fact that recovery from VL is always
associated with immunity to subsequent infection and induction of
Th1 cytokines dominated by IFN-c, we identified several Th1
stimulatory proteins from soluble fraction and sub-fraction of L.
donovani ranging from 89.9 to 97.1 kDa through proteomics which
was also found to be protective against experimental VL
[15,16,52]. Triose phosphate isomerase of L. donovani (LdTPI), a
vital glycolytic enzyme, was one such Th1 stimulatory protein
identified from the above stated fraction of soluble Leishmania
antigen. In this study, we have re-assessed LdTPI for its possible
immunogenic and prophylactic potential against VL. LdTPI,
which was cloned, expressed and purified, has the homology with
L. infantum TPI to the tune of 99%. Immunoblot study of L.donovani
promastigote lysate with the polyclonal anti-rLdTPI antibody
revealed one dominant protein of ,27 kDa. The presence of this
protein in higher molecular weight range in proteomic studies, in
contrast to its observed molecular mass could be attributed to the
post-translational modifications which are widely prevalent in
Leishmania.
When evaluated for its immunogenicity by LTT and cytokine
responses in PBMCs from cured/endemic/infected kala-azar
patients, we observed ,2.0 to 4.0 times better proliferative
response as well as IFN-a˜ and IL-12 in comparison to SLD and
low concentration of IL-10 in culture supernatants of rLdTPI -
induced PBMCs from cured kala-azar patients as well as endemic
contacts. It is likely that the individuals from the endemic area are
mostly exposed thus exhibiting such levels of responses. As
expected, rLdTPI did not induce proliferation or cytokine
production in healthy subjects, suggesting its specificity toward
L. donovani infection. The analysis of cellular immune response of
the rLdTPI was further validated in hamsters’ lymphocytes/
macrophages in order to correlate the observations made with the
human PBMCs as the systemic infection of the hamster with L.
donovani is very similar to human kala-azar [22]. In the absence of
cytokine reagents against hamsters, we have evaluated the effect of
rLdTPI on LTT and NO production by peritoneal macrophages
of hamster. It is well documented that in case of leishmanial
infections, macrophages become activated by IFN-c released from
parasite-specific T cells, and are able to destroy intracellular
parasites through the production of several mediators, principal
among which is NO [53,54]. rLdTPI gave significantly higher
cellular responses viz. LTT as well as NO release against all the
cured hamsters in comparison to normal and infected ones. The
limitations of this in vitro study based on a convenience human
sampling, may not perhaps allow drawing solid conclusions
regarding the immunogenicity of rLdTPI. However, since the
cellular responses of the antigen in human subjects were further
validated in cured hamsters, our findings therefore accentuate that
L. donovani-primed PBMCs from cured kala-azar patients and
hamsters after stimulation with rLdTPI exhibit a strong Th1-type
cellular response, which should be protective in nature.
Successful immunization that induces protection against leish-
maniasis is highly dependent on adjuvants or delivery system that
preferentially stimulates the Th1 phenotype of immune response
and plasmid DNA is one of the most interesting vaccine delivery
system. In contrast to conventional immunization that results in
stimulating primarily CD4-T-cell responses, DNA immunization
has been shown to stimulate both CD4- and CD8-T-cell responses
[55,56,57]. Based on this, in the present study, we carried out
DNA vaccination with LdTPI- DNA in hamsters and challenged
with the virulent strain of L. donovani. The immunized hamsters
survived the lethal challenge and remained healthy more than 8
months, whereas all non-immunized and blank vector-immunized
Figure 7. Anti- Leishmania-specific IgG and its isotypes IgG1
and IgG2 in LdTPI-DNA vaccinated hamsters in comparison to
the unimmunized infected hamsters on days 45 and 90 p.c.
Significance values indicate the difference between the vaccinated
group and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0045766.g007
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hamsters succumbed to the lethal L. donovani challenge within 3–
4 mo p.c.
We further assessed whether the vaccination with LdTPI-DNA
was able to generate immune response in hamsters since, a major
factor of the immune mechanism(s) is the development of strong
CMI responses like T-cell responses, NO production and DTH
responses which are responsible for protection and are also
supposed to contribute to healing in VL [41,58,59,60]. In the
present study, it was evident that all LdTPI-DNA vaccinated
hamsters challenged with L. donovani have a specific active T-cell
response because they displayed significant LTT response after
challenge; on the other hand, this response was severely impeded
in non-immunized infected and healthy control hamsters. Further,
the supernatant of SLD-stimulated lymphocytes from LdTPI-DNA
vaccinated hamsters produced a remarkable level of NO in the
macrophages of naive hamsters which also supported the view
regarding the up-regulation of iNOS by Th1 cell-associated
cytokines and confirms that the NO-mediated macrophage
effector mechanism is critical in the control of parasite replication
in the animal model [61]. In addition, successful vaccination of
humans and animals is often related to antigen-induced DTH
responses in vivo and T-cell stimulation with antigen in vitro [22,62],
suggesting a correlation between CMI responses and immunity to
infection in this model. There was a low level of parasite-specific
DTH responses observed in infected and vector control animals
which, on the other hand, was strongly expressed in hamsters
immunized with DNA vaccine. Apart from diminished cellular
responses, active VL is also associated with the production of high
levels of the Leishmania specific antibody particularly IgG and
IgG1, which are observed before detection of parasite-specific T
cell response [63]. On the other hand, as a measure of CMI, the
elevation of IgG2 is consistent with the development of effective
immune responses [33]. The transcript of IFN-c, a signature
cytokine of the Th1-type response that has a dominant effect on
macrophage microbicidal responses and other effector killing
mechanisms, along with TNF-a´, often reported to act in concert to
activate iNOS for the production of NO [64,65], were found to be
down-regulated [58] in infected hamsters, whereas their expres-
sion was observed to be increased many fold in the immunized
hamsters. We have also found an extreme down-regulation in the
of IL-10, reported to be down regulate IL-12 for disease
progression [66] and IL-4, considered to be a marker for Th2
response [67], in LdTPI-DNA vaccinated hamsters compared with
infected control hamsters. The level of other Th1 cytokine-IL-12,
an immune-regulatory cytokine for initiation and maintenance of
the Th1 response and plays an important role in the induction of
IFN-a˜ production by T and NK cells [68,69,70], was completely
down-regulated in infected hamster, where as high levels of IL-12
mRNA transcripts were observed in vaccinated hamsters. How-
ever, TGF-aˆ-a pleiotropic cytokine, having immunosuppressive
properties, is also documented in leishmania disease progression
[71] and known to be expressed at a moderate level even in
normal hamsters [22,41,58], was apparently down-regulated in all
the immunized hamsters throughout the experiment. Further, it
has been well established that level of IgG and IgG1 antibody
increases with the L. donovani loads [41], which however, was
present at very low level in the vaccinated group and thus
consistent with the decreasing parasite loads. The significant
increase in the IgG2 levels in the vaccinated animals only is a
phenotypic marker of enhanced CMI.
In a nutshell, our studies have for the first time indicated that
LdTPI, a glycolytic enzyme, is also capable of inducing a robust
cellular immune response in vitro against both L. donovani-primed
lymphocytes from cured kala-azar patients and hamsters and also
eliciting a strong protective response against experimental VL.
Hence, the significant immunogenic and prophylactic efficacy of
LdTPI-DNA makes it a strong and ideal prophylactic vaccine
candidate.
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